hypertension
Conditions
Interventions
Group of azilsartan:azilsartan treatment
Group of Valsartan: Valsartan treatment
Sponsors
Qilu Hospital of Shandong University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.1 Male or female patients aged 18-75; 1.2 Meet the diagnostic criteria for mild to moderate essential hypertension (the average DBP of 3 sitting positions is =95mmHg (1mmHg=0.1333kPa), and <110mmHg; and the average value of SBP of 3 sitting positions is <180mmHg); 1.3 Screen patients with non-dipper blood pressure rhythm through 24-hour ambulatory blood pressure monitoring (24hABPM); 1.4 Subjects or their guardians agree to participate in this study.
Exclusion criteria
Exclusion criteria: 2.1 Secondary hypertension; 2.2 Intolerance of ACEI, ARB or CCB drug therapy in the past, or taking experimental drugs; 2.3 Severe liver or kidney disease (ALT=3 times the upper limit of normal; eGFR35% when screening to randomization); 2.4 Serum potassium>5.2mmol/L at screening, or blood potassium>5.4mmol/L at the end of the lead-in period; 2.5 Symptomatic hypotension, SBP 8%); 2.10 Takayasu arteritis, Kawasaki disease, coronary artery malformation; 2.11 Those who are pregnant or breastfeeding, or who intend to give birth within one year; 2.12 Other clinically significant diseases such as stroke, hemorrhage, and malignant tumors may cause serious danger to patients; 2.13 Patients who participated in clinical research of other drugs within 3 months before enrollment; 2.14 The investigator judges that the patient has any conditions that are not suitable for participating in this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ambulatory blood pressure; | — |
Secondary
| Measure | Time frame |
|---|---|
| Echocardiography;blood routine;urine routine;Blood chemistry;liver function;kidney function;Glycated hemoglobin;blood lipid; | — |
Countries
China
Contacts
Public ContactTi Yun
Qilu Hospital of Shandong University
Outcome results
None listed